Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Fifth, the short duration of each treatment phase (1 month) and absence of long-term follow-up preclude conclusions about sustained efficacy, safety, and adherence
Data sources The input parameters for the benefit-harm balance modelling were the relative treatment effects of GLP-1 RAs as compared to placebo, the benefit and harm outcome incidences in untreated individuals, and preference weights (relative importance) of the outcomes.24, 25, 26, 27 A careful selection of valid and applicable evidence relevant to the given decision context is a key step in a benefit-harm analysis.28, 29, 30 The relative treatment effect and baseline risks were obtained from RCTs
By stimulating insulin release and reducing glucagon secretion, GLP-1 efficiently lowers blood sugar levels while promoting a sense of fullness to support weight loss
31, 881890.10.1017/S003329170100407X 206 LucasA
